Hepatitis C is primarily to blame for liver cancer, one of the deadliest cancers. In addition, complications of fatty liver disease are also a cause of liver cancer. At present, researchers are trying to treat liver cancer by improving microbubbles. Microbubbles, including the sturdy outer shell and small gas bubbles inside the gas, insert glass radiation beads into the liver, and then inject the microbubbles into the blood. It is usually used in combination with radiation therapy for the treatment of advanced liver cancer.
Dr. John Eisenbrey, a radiology researcher at Thomas Jefferson University, said, “focusing the ultrasound beam on the liver tumor, the bubbles participate in the blood circulation in the body. The ultrasound only focuses on the tumor itself, and it does not affect the surrounding healthy tissue, and only generates bubbles inside the tumor. The blood supply through the catheter is only deposited in the tumor. When the bubbles burst, it will enhance the radiation effect. This therapy is to destroy the blood supply and starve the tumor, and then the tumor begins to shrink over time. It is still in The early stages of clinical trials have shown good results.
At present, researchers are using commercial bubbles outside the label, and at the same time working with chemists and engineers to put chemotherapy drugs, oxygen and other compositions into microbubbles to circulate in the blood to achieve the purpose of shrinking tumors and extending the life of patients.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
